Terminal › Stocks › ELAB

PMGC Holdings Inc. (ELAB) Stock

Healthcare · Biotechnology · US

$5.91 +31.33%

Last updated Jun 18, 2026 23:56 UTC

ELAB Key Statistics

Market Cap$11.45M

P/E (TTM)-0.01

P/S (TTM)19.40

P/B (TTM)0.02

Revenue (TTM)$590,084.00

EPS (TTM)$-449.60

Dividend Yield—

ROE (TTM)-92.02%

Net Margin-1,306.28%

Gross Margin12.68%

52W High$14.00

52W Low$1.62

Analyst View—

Price Target—

Employees2

Volume51,405,214

About PMGC Holdings Inc.

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

CEO: Graydon Bensler. Company website

See ELAB live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open ELAB in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.